289 related articles for article (PubMed ID: 9102222)
21. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
22. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
[TBL] [Abstract][Full Text] [Related]
23. Specific antibody production to a recall or a neoantigen by SCID mice reconstituted with human peripheral blood lymphocytes.
Nonoyama S; Smith FO; Ochs HD
J Immunol; 1993 Oct; 151(7):3894-901. PubMed ID: 8376809
[TBL] [Abstract][Full Text] [Related]
24. [Development of HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and its immunological features].
Liang ZX; Cheng Q; Chen HZ; Xie X; Ye DF
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1465-9. PubMed ID: 15500747
[TBL] [Abstract][Full Text] [Related]
25. [Antitumor effect of gene therapy with recombinant adenovirus-mediated human interleukin-2 gene transfer and its mechanism].
Du J; Ran Y; Lin Z; Zheng C; Wei H; Wang X; Zhou L; Ren Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):12-5. PubMed ID: 15600167
[TBL] [Abstract][Full Text] [Related]
26. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
27. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
[TBL] [Abstract][Full Text] [Related]
28. Targeting p53 for adoptive T-cell immunotherapy.
McCarty TM; Liu X; Sun JY; Peralta EA; Diamond DJ; Ellenhorn JD
Cancer Res; 1998 Jun; 58(12):2601-5. PubMed ID: 9635585
[TBL] [Abstract][Full Text] [Related]
29. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.
Mazzolini G; Qian C; Xie X; Sun Y; Lasarte JJ; Drozdzik M; Prieto J
Cancer Gene Ther; 1999; 6(6):514-22. PubMed ID: 10608348
[TBL] [Abstract][Full Text] [Related]
30. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
31. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
32. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.
Somasundaram R; Jacob L; Swoboda R; Caputo L; Song H; Basak S; Monos D; Peritt D; Marincola F; Cai D; Birebent B; Bloome E; Kim J; Berencsi K; Mastrangelo M; Herlyn D
Cancer Res; 2002 Sep; 62(18):5267-72. PubMed ID: 12234995
[TBL] [Abstract][Full Text] [Related]
34. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
35. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor.
Kanagawa N; Gao JQ; Motomura Y; Yanagawa T; Mukai Y; Yoshioka Y; Okada N; Nakagawa S
Biochem Biophys Res Commun; 2008 Aug; 372(4):821-5. PubMed ID: 18519033
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
37. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
38. Deficient cytokine response of human allergen-specific T lymphocytes from humanized SCID mice and reconstitution by professional antigen-presenting cells.
Jarman ER; Perschke K; Montermann E; Herz U; Renz H; Knop J; Reske-Kunz AB
J Allergy Clin Immunol; 2000 May; 105(5):967-74. PubMed ID: 10808178
[TBL] [Abstract][Full Text] [Related]
39. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
Wang L; Qi X; Sun Y; Liang L; Ju D
Cancer Gene Ther; 2002 Oct; 9(10):819-24. PubMed ID: 12224022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
